Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 13/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GPR183 | P32249 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500019 | 0.85 | ALDH1A1 (0.44) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL499800 | 0.84 | SLC5A2 (0.48) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL12782162 | 0.81 | CCR5 (0.47) | HTR2ASLC6A4KCNH2CCR5MEN1 | |
| SCHEMBL5681425 | 0.81 | SLC5A2 (0.33) | SLC5A2SLC5A1CCR5 | |
| SCHEMBL500031 | 0.80 | SLC6A4 (0.37) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL37715 | 0.78 | SLC5A2 (0.47) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL499287 | 0.78 | SLC5A2 (0.38) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL1457579 | 0.78 | APP (0.40) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL17842 | 0.78 | MEN1 (0.46) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 | |
| SCHEMBL29816996 | 0.78 | MEN1 (0.46) | SLC5A2SLC5A1HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936590-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1224195-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | disclosed |
| EP-1224195-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414126-B1 | ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885HTR2A 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.